DSGN
Design Therapeutics, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
PositiveDesign Therapeutics reported Q2 2026 results with a $20.2M net loss and $207.4M in cash, while announcing positive modifications to its lead RESTORE-FA trial for Friedreich ataxia based on encouraging four-week efficacy and safety data showing dose-dependent frataxin increases. The company is advancing its pipeline with DT-818 Phase 1 dosing in myotonic dystrophy and expects registrational guidance and 12-week RESTORE-FA data in Q4 2026 and Q1 2027, respectively.
Red flags
- •Cash burn of $12.4M in H1 2026 ($24.8M annualized run rate) with $207.4M runway supporting ~8-9 years at current burn, but clinical-stage biotech requires successful trial outcomes
- •RESTORE-FA trial design shift to single dose focus (1 mpk) with only 10 patients in primary cohort introduces concentration risk if efficacy plateaus or fails to replicate
Fund 13D/13G Filings (4)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
Tracked Funds Holding (1)
| Fund | Manager | Shares Held | Position Value |
|---|---|---|---|
| Point72 | Steve Cohen | 2.4M | $34M |
Quarter-end 13F positions for the tracked funds holding this stock.